Published in N Engl J Med on August 27, 1998
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ (2013) 3.51
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34
Protecting the confidentiality of interim data: addressing current challenges. Clin Trials (2014) 3.33
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant (2014) 2.91
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol (2008) 2.72
Performance variability of seven commonly used self-monitoring of blood glucose systems: clinical considerations for patients and providers. J Diabetes Sci Technol (2013) 2.58
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int (2012) 2.35
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol (2010) 2.22
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol (2012) 2.03
Mechanisms of anemia in CKD. J Am Soc Nephrol (2012) 1.91
Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis (2009) 1.79
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int (2009) 1.72
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis (2012) 1.69
Improving outcomes for ESRD patients: shifting the quality paradigm. Clin J Am Soc Nephrol (2013) 1.62
Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ (2009) 1.61
Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol (2007) 1.61
Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol (2009) 1.59
Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med (2014) 1.58
Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.54
Biomarkers and surrogate endpoints in clinical trials. Stat Med (2012) 1.53
Clinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device. JACC Heart Fail (2015) 1.53
Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis (2013) 1.52
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int (2006) 1.50
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.49
Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev (2013) 1.47
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth (2011) 1.43
Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int (2008) 1.34
Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol (2012) 1.33
Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin J Am Soc Nephrol (2009) 1.32
Erythropoietin. Cold Spring Harb Perspect Med (2013) 1.28
IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol (2011) 1.21
Chronic kidney disease and its complications. Prim Care (2008) 1.19
Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol (2015) 1.16
The normal hematocrit study--follow-up. N Engl J Med (2008) 1.16
Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2012) 1.15
Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol (2008) 1.14
Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol (2009) 1.13
Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol (2010) 1.12
Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ (2008) 1.12
Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol (2014) 1.11
Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol (2009) 1.10
Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer (2009) 1.09
Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol (2009) 1.09
Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. Health Aff (Millwood) (2012) 1.07
Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol (2010) 1.07
Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol (2013) 1.06
Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care (2007) 1.06
An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol Syst Biol (2007) 1.05
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.05
Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A (2006) 1.05
The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol (2008) 1.04
Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis (2012) 1.04
Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol (2009) 1.01
The effect of altitude on dosing and response to erythropoietin in ESRD. J Am Soc Nephrol (2008) 1.00
Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) (2012) 1.00
Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol (2009) 1.00
Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. Saudi J Gastroenterol (2008) 1.00
Effect of processing and storage on red blood cell function in vivo. Semin Perinatol (2012) 1.00
Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol (2010) 1.00
Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant (2010) 0.99
Management of anemia in children receiving chronic peritoneal dialysis. J Am Soc Nephrol (2013) 0.99
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol (2015) 0.98
Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol (2015) 0.97
Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol (2013) 0.96
Erythropoietic stress and anemia in diabetes mellitus. Nat Rev Endocrinol (2009) 0.96
Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev (2008) 0.96
Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol (2009) 0.96
Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol (2012) 0.95
Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med (2009) 0.94
Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int (2014) 0.94
Determining optimum hemoglobin sampling for anemia management from every-treatment data. Clin J Am Soc Nephrol (2010) 0.94
The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant (2013) 0.93
The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol (2009) 0.93
Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology (2012) 0.93
Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag (2009) 0.92
Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One (2010) 0.92
Predictors of quality of life of hemodialysis patients in India. Indian J Nephrol (2012) 0.91
Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol (2011) 0.90
Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol (2013) 0.90
Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat. J Pharm Bioallied Sci (2012) 0.89
Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. J Am Soc Nephrol (2015) 0.89
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica (2011) 0.89
Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol (2008) 0.89
Anemia in children with chronic kidney disease. Pediatr Nephrol (2007) 0.89
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant (2013) 0.88
The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients. Clin Exp Nephrol (2012) 0.88
The new FDA labeling for ESA--implications for patients and providers. Clin J Am Soc Nephrol (2012) 0.88
Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Med Care (2014) 0.87
Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int (2011) 0.87
Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol (2007) 0.87
A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Curr Ther Res Clin Exp (2013) 0.87
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol (2014) 0.86
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol (2016) 0.86
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med (1987) 5.57
Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A (1985) 3.28
Isolation, characterization, and comparison of recombinant DNAs derived from genomes of human hepatitis B virus and woodchuck hepatitis virus. Proc Natl Acad Sci U S A (1980) 3.04
Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med (1989) 2.43
Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med (1997) 2.10
Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant (2011) 2.10
Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis (1999) 2.03
Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol (1992) 1.92
Acute renal failure in critically ill patients: prognosis for recovery of kidney function after prolonged dialysis support. Crit Care Med (1991) 1.82
Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients. Am J Transplant (2011) 1.79
Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med (1987) 1.76
Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer (2001) 1.72
Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother (1981) 1.66
Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int (2000) 1.52
Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother (1981) 1.51
Comparative pharmacology of josamycin and erythromycin stearate. Antimicrob Agents Chemother (1976) 1.46
Crescentic glomerulonephritis without immune deposits: clinicopathologic features. Kidney Int (1979) 1.45
Vascular access: concepts for the 1990s. J Am Soc Nephrol (1992) 1.44
Comparison of transposed brachiobasilic fistulas to upper arm grafts and brachiocephalic fistulas. Kidney Int (2001) 1.44
Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab (1993) 1.42
Erythropoietin and peritoneal dialysis: the efficacy of intraperitoneal dosing. Perit Dial Int (1992) 1.41
Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant (2001) 1.40
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int (2000) 1.37
Human ribosomal RNA gene spacer sequences are found interspersed elsewhere in the genome. Gene (1981) 1.36
Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Hemodialysis (HEMO) Study Group. Kidney Int (2000) 1.35
Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother (1980) 1.34
Massive proteinuria and acute renal failure in a patient with acute silicoproteinosis. Am J Med (1978) 1.32
Acute silicosis in tombstone sandblasters. Am Rev Respir Dis (1977) 1.31
A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int (2000) 1.29
Spontaneous glomerular sclerosis in aging Sprague-Dawley rats. I. Lesions associated with mesangial IgM deposits. Am J Pathol (1976) 1.27
Intravenous pulse methylprednisolone therapy of acute crescentic rapidly progressive glomerulonephritis. Am J Med (1979) 1.27
rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int (1991) 1.27
Chronic autologous immune complex glomerulopathy: effect of cyproheptadine. J Lab Clin Med (1974) 1.24
Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother (1983) 1.23
Nucleotide sequences from the rabbit beta globin gene inserted into Escherichia coli plasmids. Science (1977) 1.21
Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods (1987) 1.21
Characterization and biological effects of recombinant human erythropoietin. Immunobiology (1986) 1.20
USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol (1989) 1.20
Renal infection in autosomal dominant polycystic kidney disease. Am J Med (1987) 1.20
Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thorac Surg (1997) 1.12
New avian model of experimental glomerulonephritis consistent with mediation by cellular immunity. Nonhumorally mediated glomerulonephritis in chickens. J Clin Invest (1984) 1.12
Survival in renal vascular disease. J Am Soc Nephrol (1998) 1.11
The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol (1996) 1.10
Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med (1989) 1.08
Rapidly progressive silicon nephropathy. Am J Med (1981) 1.08
Conversion of a Golgi apparatus sialyltransferase to a secretory protein by replacement of the NH2-terminal signal anchor with a signal peptide. J Biol Chem (1989) 1.06
Correction of central venous stenoses: use of angioplasty and vascular Wallstents. Kidney Int (1994) 1.06
Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function. Antimicrob Agents Chemother (1978) 1.06
The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients? Semin Dial (2001) 1.05
Ventriculojugular shunt nephritis with Corynebacterium bovis. Successful therapy with antibiotics. Am J Med (1975) 1.05
Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int (1998) 1.03
An evaluation of diabetic and pseudodiabetic glomerulosclerosis. Am J Med (1979) 1.02
Characterization of recombinant monkey and human erythropoietin. Prog Clin Biol Res (1985) 1.01
Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J (1998) 1.01
Isolation, characterization, and expression of a cDNA encoding N-acetylglucosaminyltransferase V. J Biol Chem (1993) 1.00
Quality of life in chronic dialysis patients: a critical comparison of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Am J Kidney Dis (1988) 0.99
The safety of epoetin-alpha: results of clinical trials in the United States. Contrib Nephrol (1991) 0.99
Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int (2000) 0.97
Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J Kidney Dis (1996) 0.96
Mannitol. West J Med (1979) 0.95
Membranoproliferative glomerulonephritis with primary Sjögren's syndrome. Am J Kidney Dis (1995) 0.94
Erythropoietin and anemia. Semin Nephrol (2001) 0.94
Rheumatoid factor inhibition of in vitro binding of IgG complexes in the human glomerulus. Arthritis Rheum (1982) 0.93
Penetration of trimethoprim and sulfamethoxazole into cysts in a patient with autosomal-dominant polycystic kidney disease. Am J Kidney Dis (1986) 0.92
Hemodiabsorption in treatment of hepatic failure. J Transpl Coord (1998) 0.92
Autoimmune glomerulotubular nephropathy in mice. Clin Exp Immunol (1978) 0.92
Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol (1986) 0.92
Poststreptococcal acute glomerulonephritis: fact and controversy. Ann Intern Med (1979) 0.91
Hemodialysis in the treatment of psoriasis. A controlled trial. Ann Intern Med (1979) 0.91
Mechanisms of angioplasty in hemodialysis fistula stenoses evaluated by intravascular ultrasound. Kidney Int (1991) 0.91
Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol (1996) 0.91
Perioperative recombinant human erythropoietin. Surgery (1989) 0.90
Reversible renal failure from isolated granulomatous renal sarcoidosis. Clin Nephrol (1976) 0.90
Bovine serum albumin chronic serum sickness nephropathy in rats. Br J Exp Pathol (1978) 0.90
Therapy of the idiopathic nephrotic syndrome with alternate day steroids. Am J Med (1977) 0.89
Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Ann Thorac Surg (1994) 0.89
Adverse ocular effects of acetate hemodialysis. Am J Nephrol (1983) 0.89
Suppression of cutaneous perception by magnetic pulse stimulation of the human brain. Electroencephalogr Clin Neurophysiol (1992) 0.89
Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. J Am Vet Med Assoc (1998) 0.89
Na+ gradient-dependent Pi uptake in basolateral membrane vesicles from dog kidney. Am J Physiol (1984) 0.88
Partial characterization of three distinct populations of human gamma-crystallins. Invest Ophthalmol Vis Sci (1985) 0.88
Spontaneous rupture of the liver. An unusual complication of SLE. Arthritis Rheum (1977) 0.88
National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis (1993) 0.88
Improved urea reduction ratio and Kt/V in large hemodialysis patients using two dialyzers in parallel. Am J Kidney Dis (2000) 0.88
Requirement of functional T-cells in the production of autoimmune glomerulotubular nephropathy in mice. Clin Exp Immunol (1978) 0.87
Dialysis access infections. Curr Opin Nephrol Hypertens (2000) 0.87
Treatment compliance in end-stage renal disease patients on dialysis. Am J Nephrol (1986) 0.87
Clinical identification of nondiabetic renal disease in diabetic patients with type I and type II disease presenting with renal dysfunction. Am J Nephrol (1988) 0.86
The role of the anion gap in detecting and managing mixed metabolic acid-base disorders. Clin Endocrinol Metab (1984) 0.86
Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol (1991) 0.86
Adequacy of haemodialysis with cuffed central-vein catheters. Nephrol Dial Transplant (1998) 0.86
Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients. Am J Nephrol (1985) 0.86